The role of bortezomib in the treatment of lymphoma

Cancer Investigation

Volumn 25, Issue 8, 2007, Pages 766-775

  Barr, Paul ^a,c   Fisher, Richard ^b   Friedberg, Jonathan ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Chemotherapy; Lymphoma; Treatment

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; GX 15070; NPI 0052; OBLIMERSEN; PERIFOSTINE; PR 171; PREDNISONE; RITUXIMAB; UCL 67022; UNCLASSIFIED DRUG; VINCRISTINE; WP 1130;

ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GASTROINTESTINAL DISEASE; HODGKIN DISEASE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LARGE CELL LYMPHOMA; LUNG FIBROSIS; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW; SEPSIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, MANTLE-CELL; PROTEASE INHIBITORS; PYRAZINES;

EID: 36849008606     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701579570     Document Type: Review

References (86)

1. Fisher, S.G.; Fisher, R.I. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004, 23, 6524-6534.
2. SEER: Surveillance, Epidemiology & End Results Program Public-Use Data 1975-2004, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2007.
3. Campo, E.; Raffeld, M.; Jaffe, E.S. Mantle-cell lymphoma. Semin. Hematol. 1999, 36, 115-127.
4. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89, 3909-3918.
5. Fisher, R.I.; LeBlanc, M.; Press, O.W.; Maloney, D.G.; Unger, J.M.; Miller, T.P. New treatment options have changed the survival of patients with follicular lymphoma. J. Clin. Oncol. 2005, 23, 8447-8452.
6. Mani, A.; Gelmann, E.P. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. 2005, 23, 4776-4789.
7. Ling, Y.H.; Liebes, L.; Jiang ,J.D.; Holland, J.F.; Elliott, P.J.; Adams, J.; Muggia, F.M.; Perez-Soler, R. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. 2003, 9, 1145-1154.
8. Adams, J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 2004, 4, 349-360.
9. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5, 417-421.
10. Almond, J.B.; Cohen, G.M. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002, 16, 433-443.
11. Orlowski, R.Z.; Baldwin, A.S., Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 2002, 8, 385-389.
12. Heckman, C.A.; Mehew, J.W.; Boxer, L.M. NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002, 21, 3898-3908.
13. Rao, P.H.; Houldsworth, J.; Dyomina, K.; Parsa, N.Z.; Cigudosa, J.C.; Louie, D.C.; Popplewell, L.; Offit, K.; Jhanwar, S.C.; Chaganti, R.S. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998, 92, 234-240.
14. Feuerhake, F.; Kutok, J.L.; Monti, S.; Chen, W.; LaCasce, A.S.; Cattoretti, G.; Kurtin, P.; Pinkus, G.S.; de Leval, L.; Harris, N.L.; Savage, K.J.; Neuberg, D.; Habermann, T.M.; Dalla-Favera, R.; Golub, T.R.; Aster, J.C.; Shipp, M.A. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005, 106, 1392-1399.
15. Ni, H.; Ergin, M.; Huang, Q.; Qin, J.Z.; Amin, H.M.; Martinez, R.L.; Saeed, S.; Barton, K.; Alkan, S. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br. J. Haematol. 2001, 115, 279-286.
16. Izban, K.F.; Ergin, M.; Huang, Q.; Qin, J.Z.; Martinez, R.L.; Schnitzer, B.; Ni, H.; Nickoloff, B.J.; Alkan, S. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod. Pathol. 2001, 14, 297-310.
17. Martinez-Delgado, B.; Cuadros, M.; Honrado, E.; Ruiz de la Parte, A.; Roncador, G.; Alves, J.; Castrillo, J.M.; Rivas, C.; Benitez, J. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 2005, 19, 2254-2263.
18. Karin, M.; Cao, Y.; Greten, F.R.; Li, Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2, 301-310.
19. Pham, L.V.; Tamayo, A.T.; Yoshimura, L.C.; Lo, P.; Ford, R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J. Immunol. 2003, 171, 88-95.
20. Strauss, S.J.; Maharaj, L.; Hoare, S.; Johnson, P.W.; Radford, J.A.; Vinnecombe, S.; Millard, L.; Rohatiner, A.; Boral, A.; Trehu, E.; Schenkein, D.; Balkwill, F.; Joel, S.P.; Lister, T.A. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J. Clin. Oncol. 2006, 24, 2105-2112.
21. Warzocha,, K.; Salles, G.; Bienvenu, J.; Bastion, Y.; Dumontet, C.; Renard, N.; Neidhardt-Berard, E.M.; Coiffier, B. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J. Clin. Oncol. 1997, 15, 499-508.
22. Zinzani, P.L.; Baccini, C.; Zaccaria, A.; Visani, G.; Buzzi, M.; Morelli, A.; Molinari, A.L.; Salvucci, M.; Bendandi, M.; Rubboli, D.; Gherlinzoni, F.; Zanchini, R.; Tura, S. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma. Eur. J. Haematol. 1996, 57, 335-340.
23. Masdehors, P.; Merle-Beral, H.; Maloum, K.; Omura, S.; Magdelenat, H.; Delic, J. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 2000, 96, 269-274.
24. Kurland, J.F.; Meyn, R.E.; Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells. Int. J. Cancer 2001, 96, 327-333.
25. Leitch, D.; Barrans, S.L.; Jack, A.S.; Owen, R.G. Dysregulation of apoptosis in Waldenstrom's macroglobulinemia does not involve nuclear factor kappa B activation. Semin. Oncol. 2003, 30, 161-164.
26. Kashkar, H.; Deggerich, A.; Seeger, J.M.; Yazdanpanah, B.; Wiegmann, K.; Haubert, D.; Pongratz, C.; Kronke, M. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood 2007, 109, 3982-3988.
27. Bogner, C.; Ringshausen, I.; Schneller, F.; Fend, F.; Quintanilla-Martinez, L.; Hacker, G., Goetze, K.; Oostendorp, R.; Peschel, C.; Decker, T. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells. Br. J. Haematol. 2003, 122, 260-268.
28. Shringarpure, R.; Catley, L.; Bhole, D.; Burger, R.; Podar, K.; Tai, Y.T.; Kessler, B.; Galardy, P.; Ploegh, H.; Tassone, P.; Hideshima, T.; Mitsiades, C.; Munshi, N.C.; Chauhan, D.; Anderson, K.C. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br. J. Haematol. 2006, 134, 145-156.
29. Strauss, S.J.; Higginbottom, K.; Juliger, S.; Maharaj, L.; Allen, P.; Schenkein, D.; Lister, T.A.; Joel, S.P. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. 2007, 67, 2783-2790.
30. Perez-Galan, P.; Roue, G.; Villamor, N.; Montserrat, E.; Campo, E.; Colomer, D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107, 257-264.
31. Kukreja, A.; Hutchinson, A.; Mazumder, A.; Vesole, D.; Angitapalli, R.; Jagannath, S.; O'Connor, O.A.; Dhodapkar, M.V. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications. Br. J. Haematol. 2007, 136, 106-110.
32. Hideshima, T.; Richardson, P.; Chauhan, D.; Palombella, V.J.; Elliott, P.J.; Adams, J.; Anderson, K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61, 3071-3076.
33. Roue, G.; Perez-Galan, P.; Lopez-Guerra, M.; Villamor, N.; Campo, E.; Colomer, D. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J. Immunol. 2007, 178, 1923-1930.
34. Orlowski, R.Z.; Eswara, J.R.; Lafond-Walker, A.; Grever, M.R.; Orlowski, M.; Dang, C.V. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998, 58, 4342-4348.
35. Adams, J.; Palombella, V.J.; Sausville, E.A.; Johnson, J.; Destree, A.; Lazarus, D.D.; Maas, J.; Pien, C.S.; Prakash, S.; Elliott, P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59, 2615-2622.
36. Sun, X.M.; Butterworth, M.; MacFarlane, M.; Dubiel, W.; Ciechanover, A.; Cohen, G.M. Caspase activation inhibits proteasome function during apoptosis. Mol. Cell 2004, 14, 81-93.
37. Weigert, O.; Pastore, A.; Rieken, M.; Lang, N.; Hiddemann, W.; Dreyling, M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007, 21, 524-528.
38. Haritunians, T.; Mori, A.; O'Kelly, J.; Luong, Q.T.; Giles, F.J.; Koeffler, H.P. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007, 21, 333-339.
39. O'Connor, O.A.; Smith, E.A.; Toner, L.E.; Teruya-Feldstein, J.; Frankel, S.; Rolfe, M.; Wei, X.; Liu, S.;, Marcucci, G.; Chan, K.K.; Chanan-Khan, A. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin. Cancer Res. 2006, 12, 2902-2911.
40. Perez-Galan, P.; Roue, G.; Villamor, N.; Campo, E.; Colomer, D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007, 109, 4441-4449.
41. Pham, L.V.; Tamayo, A.T.; Yoshimura, L.C.; Priebe, W.; Donato, N.J.; Talpaz, M.; Ford, R.J. Bortezomib Synergizes with a Novel Jak2 inhibitor, WP-1130, To inhibit cell growth and induce apoptosis in "Classic" and "Blastoid-Variant" mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2006, 108, 2512.
42. Maharaj, L.; Popat, R.; Chahwan, A.; Lister, A..T; Cavenagh, J.D.; Middleton, B.; Rioja, A.; Marson, C.; Joel, S.P. The novel HDAC inhibitor UCL67022 is highly potent in multiple myeloma and non-hodgkin's lymphoma and is enhanced by bortezomib. Blood (ASH Annual Meeting Abstracts) 2006, 108, 2604.
43. Heider, U.;, Kaiser, M.; Zavrski, I.; Sterz, J.; Jakob, C.; Fleissner, C.; Hecht, M.; Kleeberg, L.; Braun, C.; Possinger, K.; Sezer, O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2006, 108, 2509.
44. Lightcap, E.S.; McCormack, T.A.; Pien, C.S.; Chau, V.; Adams, J.; Elliott, P.J. Proteasome inhibition measurements: clinical application. Clin. Chem. 2000, 46, 673-683.
45. Orlowski, R.Z.; Stinchcombe, T.E.; Mitchell, B.S.; Shea, T.C.; Baldwin, A.S.; Stahl, S.; Adams, J.; Esseltine, D.L.; Elliott, P.J.; Pien, C.S.; Guerciolini, R.; Anderson, J.K.; Depcik-Smith, N.D.; Bhagat, R.; Lehman, M.J.; Novick, S.C.; O'Connor, O.A.; Soignet, S.L. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002, 20, 4420-4427.
46. Hamilton, A.L.; Eder, J.P.; Pavlick, A.C.; Clark, J.W.; Liebes, L.; Garcia-Carbonero, R.; Chachoua, A.; Ryan, D.P.; Soma, V.; Farrell, K.; Kinchla, N.; Boyden, J.; Yee, H.; Zeleniuch-Jacquotte, A.; Wright, J.; Elliott, P.; Adams, J.; Muggia, F.M. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J. Clin. Oncol. 2005, 23, 6107-6116.
47. Aghajanian, C.; Soignet, S.; Dizon, D.S.; Pien, C.S.; Adams, J.; Elliott, P.J.; Sabbatini, P.; Miller, V.; Hensley, M.L.; Pezzulli, S.; Canales, C.; Daud, A.; Spriggs, D.R. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 2002, 8, 2505-2511.
48. Meusers, P.; Engelhard, M.; Bartels, H.; Binder, T.; Fulle, H.H.; Gorg, K.; Gunzer, U.; Havemann, K.; Kayser, W.; Konig, E. et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989, 7, 365-380.
49. Romaguera, J.E.; Fayad, L.; Rodriguez, M.A.; Broglio, K.R.; Hagemeister, F.B.; Pro, B.; McLaughlin, P.; Younes, A.; Samaniego, F.; Goy, A.; Sarris, A.H.; Dang, N.H.;Wang, M.; Beasley, V.; Medeiros, L.J.; Katz, R.L.; Gagneja, H.; Samuels, B.I.; Smith, T.L.; Cabanillas, F.F. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J. Clin. Oncol. 2005, 23, 7013-7023.
50. Khouri, I.F.; Romaguera, J.; Kantarjian, H.; Palmer, J.L.; Pugh, W.C.; Korbling, M.; Hagemeister, F.; Samuels, B.; Rodriguez, A.; Giralt, S.; Younes, A.; Przepiorka, D.; Claxton, D.; Cabanillas, F.; Champlin, R. Hyper-CVADand high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J. Clin. Oncol. 1998, 16, 3803-3809.
51. Dreyling, M.; Lenz, G.; Hoster, E.; Van Hoof, A.; Gisselbrecht, C.; Schmits, R.; Metzner, B.; Truemper, L.; Reiser, M.; Steinhauer, H.; Boiron, J.M.; Boogaerts, M.A.; Aldaoud, A.; Silingardi, V.; Kluin-Nelemans, H.C.; Hasford, J.; Parwaresch, R.; Unterhalt, M.; Hiddemann, W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105, 2677-2684.
52. O'Connor, O.A.; Wright, J.; Moskowitz, C.; Muzzy, J.; MacGregor-Cortelli, B.; Stubblefield, M.; Straus, D.; Portlock, C.; Hamlin, P.; Choi, E.; Dumetrescu, O.; Esseltine, D.; Trehu, E.; Adams, J.; Schenkein, D.; Zelenetz, A.D. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 2005, 23, 676-684.
53. Goy, A.; Younes, A.; McLaughlin, P.; Pro, B.; Romaguera, J.E.; Hagemeister, F.; Fayad, L.; Dang, N.H.; Samaniego, F.; Wang, M.; Broglio, K.; Samuels, B.; Gilles, F.; Sarris, A.H.; Hart, S.; Trehu, E.; Schenkein, D.; Cabanillas, F.; Rodriguez, A.M. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2005, 23, 667-675.
54. Fisher, R.I.; Bernstein, S.H.; Kahl, B.S.; Djulbegovic, B.; Robertson, M.J.; de Vos, S.; Epner, E.; Krishnan, A.; Leonard, J.P.; Lonial, S.; Stadtmauer, E.A.; O'Connor, O.A.; Shi, H.; Boral, A.L.; Goy, A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2006, 24, 4867-4874.
55. Belch, A.; Kouroukis, C.T.; Crump, M.; Sehn, L.; Gascoyne, R.D.; Klasa, R.; Powers, J.; Wright, J.; Eisenhauer, E.A. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann. Oncol. 2007, 18, 116-121.
56. Harris, N.L.; Jaffe, E.S.; Diebold, J.; Flandrin, G.; Muller-Hermelink, H.K.; Vardiman, J.; Lister, T.A.; Bloomfield, C.D. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000, 36, 69-86.
57. Dimopoulos, M.A.; Anagnostopoulos, A.; Kyrtsonis, M.C.; Castritis, E.; Bitsaktsis, A.; Pangalis, G.A. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005, 90, 1655-1658.
58. Chen, C.I.; Kouroukis, C.T.; White, D.; Voralia, M.; Stadtmauer, E.; Stewart, A.K.; Wright, J.J.; Powers, J.; Walsh, W.; Eisenhauer, E. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1570-1575.
59. de Vos, S.; Fernando, D.; Schenkein, D.P.; Rosen, P.J. A Phase 2 Study of Bortezomib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Blood (ASH Annual Meeting Abstracts) 2005, 106, 4746.
60. Dunleavy, K.; Janik, J.; Gea-Banacloche, J.; Shovlin, M.; White, T.; Goldschmidt, N.; Grant, N.; Koc, O.; Pittaluga, S.; Jaffe, E.; Staudt, L.; Wilson, WH. Phase I/II study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 2004, 104, 1385.
61. Leonard, J.P.; Furman, R.R.; Cheung, Y.-K.K.; Feldman, E.J.; Cho, H.J.; Vose, J.M.; Nichols, G.; Glynn, P.W.; Joyce, M.A.; Ketas, J.; Ruan, J.; Carew, J.; Niesvizky, R.; LaCasce, A.; Chadburn, A.; Cesarman, E.; Coleman, M. Phase I/II Trial of Bortezomib + CHOP-Rituximab in Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphoma (MCL): Phase I Results. Blood (ASH Annual Meeting Abstracts) 2005, 106, 491.
62. Zheng, B.; Georgakis, G.V.; Li, Y.; Bharti, A.; McConkey, D.; Aggarwal, B.B.; Younes, A. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin. Cancer Res. 2004, 10, 3207-3215.
63. Younes, A.; Pro, B.; Fayad, L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 2006, 107, 1731-1732.
64. Trelle, S.; Sezer, O.; Naumann, R.; Rummel, M.; Keller, U.; Engert, A.; Borchmann, P. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica 2007, 92, 568-569.
65. Bonvini, P.; Zorzi, E.; Basso, G.; Rosolen, A. Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia 2007, 21, 838-842.
66. An, J.; Sun, Y.; Fisher, M.; Rettig, M.B. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004, 18, 1699-1704.
67. Matta, H.; Chaudhary, P.M. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol. Ther. 2005, 4, 77-82.
68. De Vos, S.; Dakhil, S.R.; McLaughlin, P.; Saleh, M.N.; Belt, R.; Flowers, C.; Holladay, C.; Knapp, M.; Boral, A.; Zhang, T.; Goy, A. Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results. Blood (ASH Annual Meeting Abstracts) 2006, 108, 694.
69. Hainsworth, J.D.; Litchy, S.; Shaffer, D.W.; Lackey, V.L.; Grimaldi, M.; Greco, F.A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 2005, 23, 1088-1095.
70. Ghielmini, M.; Schmitz, S.F.; Cogliatti, S.B.; Pichert, G.; Hummerjohann, J.; Waltzer, U.; Fey, M.F.; Betticher, D.C.; Martinelli, G.; Peccatori, F.; Hess, U.; Zucca, E.; Stupp, R.; Kovacsovics, T.; Helg, C.; Lohri, A.; Bargetzi, M.; Vorobiof, D.; Cerny, T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103, 4416-4423.
71. Treon, S.P.; Soumerai, J.D.; Patterson, C.J.; Hunter, Z.R.; Ghobrial, I.M.; Villarreal, R.; Willen, M.A.; Myers, T.J. Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstrom's Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180. Blood (ASH Annual Meeting Abstracts) 2006, 108, 2765.
72. Drach, J.; Kaufmann, H.; Pichelmayer, O.; Sagaster, V.; Seidl, S.; Chott, A.; Zielinski, C.; Raderer, M. Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 2006, 108, 2753.
73. Leleu, X.; O'Sullivan, G.; Jia, X.; Moreau, A.-S.; Ngo, H.; Hatjiharisi, E.; Yasui, H.; Hunter, Z.; Tai, Y.-T.; Runnels, J.; Treon, S.; Hideshima, T.; Anderson, K.; Ghobrial, I. Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstrom's Macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 2006, 108, 2517.
74. Orlowski, R.Z.; Voorhees, P.M.; Garcia, R.A.; Hall, M.D.; Kudrik, F.J.; Allred, T.; Johri, A.R.; Jones, P.E.; Ivanova, A.; Van Deventer, H.W.; Gabriel, D.A.; Shea, T.C.; Mitchell, B.S.; Adams, J.; Esseltine, D.L.; Trehu, E.G.; Green, M.; Lehman, M.J.; Natoli, S.; Collins, J.M.; Lindley, C.M.; Dees, E.C. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105, 3058-3065.
75. Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S.M.; Palomba, M.L.; Dumitrescu, O.-L.; Pappanicholaou, J.; Neylon, E.; Hamelers, R.; Zelenetz, A.; Myers, T.J.; Boral, A.L.; O'Connor, O.A. The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders. ASH Annual Meeting Abstracts 2006, 108, 2759.
76. Weigert, O.; Weidmann, E.; Mueck, R.; Bentz, M.; von Schilling, C.; Rohrberg, R.; Jentsch-Ullrich, K; Unterhalt, M; Hiddemann, W.; Dreyling, M.H. High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 2006, 108, 2449.
77. Wiestner, A.; Dunleavy, K.; Rizzatti, E.G.; Liu, H.; Marti, G.E.; White, T.; Wilson, W. Potent single agent activity and tumor selectivity of bortezomib in mantle cell lymphoma: first impressions from a randomized Phase II study of epoch-rituximab-bortezomib in untreated mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2005, 106, 4744.
78. Miyakoshi, S.; Kami, M.; Yuji, K.; Matsumura, T.; Takatoku, M.; Sasaki, M.; Narimatsu, H.; Fujii, T.; Kawabata, M.; Taniguchi, S.; Ozawa, K.; Oshimi, K. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006, 107, 3492-3494.
79. Ohri, A.; Arena, F.P. Severe pulmonary complications in African-American patient after bortezomib therapy. Am. J. Ther. 2006, 13, 553-555.
80. Boyer, J.E.; Batra, R.B.; Ascensao, J.L.; Schechter, G.P. Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood 2006, 108, 1113.
81. Duek, A.; Feldberg, E.; Haran, M.; Berrebi, A. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug. Am. J. Hematol. 2007, 82, 502-503.
82. Macherla, V.R.; Mitchell, S.S.; Manam, R.R.; Reed, K.A.; Chao, T.H.; Nicholson, B.; Deyanat-Yazdi, G.; Mai, B.; Jensen, P.R.; Fenical, W.F.; Neuteboom, S.T.; Lam, K.S.; Palladino, M.A.; Potts, B.C. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J. Med. Chem. 2005, 48, 3684-3687.
83. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T.H.; Neuteboom, S.T.; Richardson, P.; Palladino, M.A.; Anderson, K.C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8, 407-419.
84. Jia, X.; Leleu, X.; Moreau, A.-S.; Hatjiharisi, E.; Ngo, H.; O'Sullivan, G.; McMillin, D.; Treon, S.; Mitsiades, C.; Hideshima, T.; Palladino, M.; Anderson, K.; Chauhan, D.; Ghobrial, I. The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia. Blood (ASH Annual Meeting Abstracts) 2006, 108, 4746.
85. Kirk, C.J.; Bennett, M.K.; Buchholz, T.J.; Demo, S.D.; Ho, M.N.; Jiang, J.; Laidig, G.J.; Lewis, E.R.; Shenk, K.D.; Smyth, M.S.; Sun, C.M.; Vallone, M.K.;Woo, T.M.; Molineaux, C.J. Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome. ASH Annual Meeting Abstracts 2005, 106, 609.
86. O'Connor, O.A.; Orlowski, R.Z.; Alsina, M.; Stewart, K.; Trudel, S.; Vallone, M.K.; Woo, T.M.; Urquilla, P.R.; Molineaux, C.J.; Goy, A. Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies. ASH Annual Meeting Abstracts 2006, 108, 2430.